Cemiplimab Metastitic Cervical Cancer | Search results

Your search for Cemiplimab Metastitic Cervical Cancer returned no results
Showing 1 to 2 of 2 results for cemiplimab metastatic cervical cancer

Sort by

Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) (TA901)
NICE is unable to make a recommendation on cemiplimab (Libtayo) for treating recurrent or metastatic cervical cancer in adults because Sanofi did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Result type
Technology appraisal guidance
Published
20 June 2023
Show all sections
Sections for TA901
- Advice
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901) [ID6610]
In development Reference number: GID-TA11850 Expected publication date: 03 September 2026
Result type
Technology appraisal guidance
Status
In development